Revenue surge for pharmaceuticals group

Clinigen, the Burton-based pharmaceuticals group, has seen revenues surge by 34% for the six months to December 31, 2016.

Profits at the firm rose from £44.1m in 2015 to £59.1m last year. This was on the back of a fall in revenues, from £157.1m to £134.6m.

Shaun Chilton, group chief executive officer of Clinigen, said: “We have delivered another strong half of progress, achieving more than 30% growth across all our key financial measures.

“Link Healthcare has achieved an outstanding performance, demonstrating the value of the acquisition. Clinical Trial Services delivered another excellent performance whilst Managed Access and Specialty Pharma continued to see strong growth. It is particularly pleasing that all the divisions contributed well to the growth.

“Our focus now is to capitalise on our international market leading positions and the geographical footprint we have built. We will also look for selective bolt-on acquisitions to enhance our product portfolio, geographical footprint and / or service capabilities.

“We have started the second half positively and are well positioned to complete another year of strong growth.”